Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Ginkgo Bioworks reports mixed Q3 results, focuses on growth strategies

Ginkgo Bioworks showed strength in cost-cutting, revenue generation, and strategic focus, despite a negative adjusted EBITDA.
Challenges include financial pressures, margin concerns, and potential risks in resource utilization and funding stability.
Opportunities lie in new offerings, AI capabilities, market expansion, and revenue scale for improved profitability.
Management's emphasis on cost reduction, revenue growth, and innovation positions the company for long-term success and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zymergen

NEW YORK , July 25, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Zymergen Inc. ("Zymergen" or the "Company") (NASDAQ: ZY), connected with the proposed acquisition of the Company by Ginkgo Bioworks Holdings, Inc. ("Ginkgo") (NYSE: DNA). Under the terms of the merger agreement, the Company's shareholders will receive 0.9179 shares of Ginkgo common stock for each Zymergen share owned, representing implied per-share merger consideration of approximately $2.68 based upon Ginkgo's July 22, 2022 closing price of $2.92.

SHAREHOLDER ALERT: Weiss Law Investigates Infrastructure and Zymergen Inc.

Wilmington, Delaware--(Newsfile Corp. - July 25, 2022) - Rigrodsky Law, P.A. is investigating Zymergen Inc. ("Zymergen") (NASDAQ GS: ZY) regarding possible breaches of fiduciary duties and other violations of law related to Zymergen's agreement to be acquired by Ginkgo Bioworks Holdings, Inc. ("Ginkgo") (NYSE: DNA). Under the terms of the agreement, Zymergen stockholders will receive 0.9179 Ginkgo shares for each Zymergen share they own.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-zymergen-inc.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Zymergen Inc. Buyout

Ginkgo Bioworks (DNA) announced it entered into a definitive agreement under which Ginkgo will acquire Zymergen. These are the details.

Why Ginkgo Bioworks (DNA) Is Buying Zymergen For $300 Million

DNA stock is down even while Ginkgo Bioworks prepares to purchase a biotech business and a large research and development site. The post Why Is Ginkgo Bioworks (DNA) Stock in the Spotlight Today?

Why Is Ginkgo Bioworks (DNA) Stock in the Spotlight Today?

The deal values Zymergen at a fraction of its $3 billion valuation at Zymergen's IPO last April.

Ginkgo Buys Embattled Biotech Firm Zymergen For Paltry $300 Million

Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platform Expect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end markets Zymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the acquisition Ginkgo's platform serves customers across industries as an enabling platform and Ginkgo will support Zymergen's plans to evaluate strategic alternatives for their Advanced Materials and Drug Discovery businesses Zymergen stockholders will own 5.25% of the pro forma combined company following the transaction BOSTON and EMERYVILLE, Calif. , July 25, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA) — the leading horizontal platform for cell programming — and the biotechnology company Zymergen (Nasdaq: ZY) announced they have entered into a definitive agreement under which Ginkgo will acquire Zymergen in an all-stock transaction that values Zymergen at an approximately $300 million market capitalization.

Ginkgo to Acquire Zymergen

Ginkgo to acquire Bayer's 175,000-square-foot Biologics R&D center and enter into a new multi-year platform collaboration with Bayer to advance several agricultural biological programs BOSTON , July 25, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the signing of a definitive agreement for the previously announced transaction with Bayer to expand Ginkgo's platform capabilities in agricultural biologicals. These capabilities will be built pursuant to a transaction in which Ginkgo will acquire Bayer's 175,000-square-foot West Sacramento Biologics Research & Development site, team, and internal discovery and lead optimization platform for approximately $83.0 million in consideration.

Ginkgo and Bayer Sign Definitive Agreement to Build Agricultural Biologicals R&D Platform Capabilities

BOSTON , July 18, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the launch of a new cell programming project as part of a broader collaboration with Sumitomo Chemical Co., Ltd  (TSE:4005), one of Japan's leading chemical companies. Through this partnership, Sumitomo Chemical will leverage Ginkgo's extensive codebase and expertise in organism engineering to produce molecules in a sustainable fashion that are used in products across a broad range of industries.

Ginkgo Bioworks Announces Latest Collaboration for Beauty and Personal Care Industry with Sumitomo Chemical

The report, "Caring at Ginkgo," outlines the company's approach to sustainability, internal governance structures, and how its cell engineering platform is deployed BOSTON , July 14, 2022 /PRNewswire/ --  Ginkgo Bioworks  (NYSE: DNA), the leading horizontal platform for cell programming, today published its inaugural Sustainability Report . The report highlights the company's vision for and approach to sustainability, includes case studies across its ecosystem, and reports data according to leading environmental, social, and governance ("ESG") frameworks.

Ginkgo Bioworks Publishes Inaugural Sustainability Report

While Ginkgo Bioworks may be a relatively unknown name to many investors, DNA stock is quite well-known to Cathie Wood and her Ark funds. The post Cathie Wood Just Doubled Down on Ginkgo Bioworks (DNA) Stock appeared first on InvestorPlace.

Cathie Wood Just Doubled Down on Ginkgo Bioworks (DNA) Stock

Ginkgo has large ambitions and a valuation to match, but the company faces technology and business model risks. The stock's recent poor performance is likely due to valuation concerns and poor sentiment towards the biotech sector in general, rather than any Ginkgo specific issues.

Ginkgo Bioworks: Multiple Layers Of Uncertainty

Aditxt Inc

Mullen Automotive

Can these penny stocks make gains this week? The post Hot Penny Stocks to Buy Today?

Hot Penny Stocks to Buy Today? Check These 3 For Your July List

Globalstar

HTG Molecular Diagnostics

Which penny stocks are you watching right now? The post Check These 3 Penny Stocks Out For Your Watchlist  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check These 3 Penny Stocks Out For Your Watchlist

DNA stock is surging higher today following large purchases from Viking Global's Andreas Halvorsen and Ark Invest's Cathie Wood. The post Billionaire Andreas Halvorsen Just Bought DNA Stock.

Billionaire Andreas Halvorsen Just Bought DNA Stock. Here's Why.

American Battery Technology Company

The following penny stocks have built up a large bubble that is yet to burst. They are likely to burst soon due to the market decline.

Beware These 7 Penny Stock Bubbles Getting Ready to Burst

Cathie Wood's Ark Invest has purchased more than 3.5 million shares of DNA stock since June 29, its first purchases in over a month. The post Cathie Wood Is Making a Big Bet on Gingko Bioworks (DNA) Stock appeared first on InvestorPlace.

Cathie Wood Is Making a Big Bet on Gingko Bioworks (DNA) Stock

Blue Hat Interactive Entertainment Technology

MSP Recovery Inc

Are these penny stocks on your watchlist right now? The post Can These Penny Stocks to Watch Continue to Climb?

Can These Penny Stocks to Watch Continue to Climb?

Cronos Group

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 7.63% to $2.68 after the company, and Cronos Group Inc (NASDAQ: CRON), announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo's platform.

Why Ginkgo Bioworks Shares Are Rising After Announcement With Partner Cronos Group

TORONTO and BOSTON , June 21, 2022 /PRNewswire/ -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos"), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) ("Ginkgo"), the leading horizontal platform for cell programming, today announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo's platform for organism design and development, Cronos has successfully achieved the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid hypothesized to reduce the appetite-enhancing property of THC.

Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone

Applied UV

China Rapid Finance

Here are three penny stocks to add to your watchlist now The post 3 Good Penny Stocks to Watch During the Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Good Penny Stocks to Watch During the Market Crash

Novavax

Novocure

Huge rebounds could be in store for these beaten-down stocks.

3 Stocks Down 50% or More That You Can Buy Right Now

BOSTON , June 10, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in Goldman Sachs' 43rd Annual Global Healthcare Conference, on June 15, 2022, at 10:40 a.m. PT. Further details, a webcast link, and a replay of the presentation, if available, will be posted on the company's investor relations website at  https://investors.ginkgobioworks.com/events.

Ginkgo Bioworks Announces Participation in Goldman Sachs 43rd Annual Global Healthcare Conference

You might want to make a small investment now, while the stock is trading under $4 a share.

Ginkgo Bioworks Is Chasing a $4 Trillion Opportunity

BOSTON , June 7, 2022 /PRNewswire/ --  Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Novo Nordisk , a leading global healthcare company, to create novel expression hosts for pharmaceutical products. Today, hundreds of millions of people are living with diabetes, obesity, and other serious chronic diseases, putting a strain on individuals, families, and healthcare systems.

Ginkgo Bioworks and Novo Nordisk to Collaborate on Expression Systems for Pharmaceutical Products

Through real-time metabolite monitoring, Bitome's technology is expected to support accelerated product development timelines across Ginkgo's portfolio of cell programs BOSTON , June 6, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that it has acquired certain assets from Bitome, a company pioneering real-time metabolite monitoring for faster biological product development. Bitome has developed technology leveraging machine learning to provide continuous monitoring of cell culture media, illuminating the performance of cells in real-time and enabling faster rates of bioprocess optimization.

News for Ginkgo Bioworks Holdings Stock (DNA)